

# FINAL PROGRAMME



## Third Joint Conference of the British HIV Association (BHIVA) *with the* British Association for Sexual Health and HIV (BASHH)

1–4 April 2014

Arena and Convention Centre Liverpool




[www.bhiva.org](http://www.bhiva.org)

[#BHIVABASHH](https://twitter.com/BHIVABASHH)

[www.bashh.org](http://www.bashh.org)

18 CPD Credits  
Unique Reference No:  
87191



## Report

*HIV treatment, so far so good...  
can we do better?*

AGENDA	
<i>Thursday 3 April 2014, 09:00-10:00, Hall 1A, Level One</i>  <i>Third Joint Congress of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH)</i>  <i>April 1-4 2014, Liverpool, UK</i>	<i>09:00-09:05</i> <i>Welcome and introductions</i> <i>Chair: Dr Mark Nelson, Chelsea and Westminster Hospital</i>
	<i>09:05-09:25</i> <i>A solid start</i> <i>Dr Nicola Mackie, St Mary's Hospital London</i>
	<i>09:25-09:50</i> <i>Could do better</i> <i>Dr Laura Waters, Mortimer Market Centre, London</i>
	<i>09:50-10:00</i> <i>Question time and meeting close</i>
COMMENTS	
<i>Great work to date! Looking forward to renewed efforts next term...</i>	

A symposium  
organised and  
funded by

**ViiV**  
Healthcare

100% dedicated to HIV

**This meeting will have promotional content**

UK/HIV/0030/14a(1)

Date of preparation: March 2014



## CONTENTS AND LOCATIONS

BHIVA & BASHH Committees .....	4
Programme Summary .....	5
Programme .....	6–18
Satellite Symposia, Seminars and Workshops .....	20–25
Exhibition Floor Plan and Exhibitors .....	26
Conference Information .....	27,28
Conference Scholarships and Awards .....	29
Social Events .....	30
BHIVA / BASHH Plenary Speakers, Biographies.....	32–36
Sponsors and Exhibitors .....	38

**Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and dining areas**

## VENUES AND LOCATIONS

**All locations are Arena and Convention Centre Liverpool, unless stated otherwise**

Registration .....	Galleria Foyer, Lower Level
Lecture Theatre .....	Hall 1A, Upper Level
Exhibition .....	Hall 2, Lower Level
Posters .....	Hall 2, Lower Level
Lunch and Refreshments .....	Hall 2, Lower Level
BHIVA / BASHH Lunchtime Workshops .....	See pages 6–18 for further details
Satellite Symposia .....	Hall 1A, Upper Level
Sponsors' Workshops .....	See pages 20–25 for further details
Speakers' Preview Room .....	Room 10, Upper Level
Sponsors' Rehearsal Room .....	Room 9, Upper Level
Welcome Reception .....	Speeches: Hall 1A, Upper Level Reception: Hall 2, Lower Level
Civic Reception .....	Matou Restaurant
Gala Dinner .....	St George's Hall

**18 CPD Credits**

**Unique reference number: 87191**

# BHIVA & BASHH COMMITTEES

## BHIVA / BASHH JOINT CONFERENCES COMMITTEE (JCC)

<b>Dr David Asboe</b>	BHIVA Chair	<b>Dr Mark Nelson</b>	BHIVA Education and Scientific Subcommittee Chair
<b>Mr Garry Brough</b>	BHIVA / BASHH Community Representative	<b>Dr Adrian Palfreeman</b>	BHIVA Vice Chair
<b>Dr Annemiek de Ruiter</b>	BHIVA Secretary	<b>Dr Daniel Richardson</b>	BASHH Conferences Secretary
<b>Dr Elizabeth Foley</b>	BASHH Invited Representative	<b>Prof Jonathan Ross</b>	BASHH Treasurer
<b>Dr Mark Lawton</b>	Local Host	<b>Dr Laura Waters</b>	BASHH Invited Representative
<b>Professor Clifford Leen</b>	BHIVA Treasurer	<b>Dr John White</b>	BASHH Invited Representative
<b>Dr Alastair Miller</b>	Local Host		

## ORAL RESEARCH JUDGING PANEL

<b>Dr Annemiek de Ruiter (Co-chair)</b>	St Thomas' Hospital, London
<b>Dr Mette Rodgers (Co-chair)</b>	Croydon University Hospital
<b>Mr Garry Brough</b>	UK Community Advisory Board (UK-CAB)
<b>Dr Mas Chaponda</b>	Royal Liverpool University Hospital
<b>Dr Lucy Dorrell</b>	University of Oxford
<b>Dr Olamide Dosekun</b>	Imperial College Healthcare NHS Trust, London
<b>Dr Emma Fox</b>	Kent Community Health NHS Trust
<b>Dr Babu Kulasegaram</b>	St Thomas' Hospital, London
<b>Dr Leena Sathia</b>	Royal Free Hampstead NHS Trust, London
<b>Dr John Sweeney</b>	Blackpool Sexual Health Services
<b>Dr Alan Tang</b>	Royal Berkshire NHS Foundation Trust, Reading
<b>Dr Melinda Tenant-Flowers</b>	King's College Hospital NHS Foundation Trust

## POSTER PRESENTATION JUDGING PANEL

<b>Dr Carol Emerson (Co-chair)</b>	The Royal Hospitals, Belfast
<b>Dr Danielle Mercey (Co-chair)</b>	Central & North West London NHS Foundation Trust
<b>Dr Sophie Brady</b>	Bradford Teaching Hospitals NHS Trust
<b>Dr Elizabeth Carlin</b>	Nottingham University Hospitals NHS Trust
<b>Dr John Evans-Jones</b>	The Countess of Chester Hospital NHS Trust
<b>Professor Anna Maria Geretti</b>	University of Liverpool
<b>Dr David Goldmeier</b>	Imperial College Healthcare NHS Trust, London
<b>Dr Margaret Kingston</b>	Central Manchester University Hospitals NHS Foundation Trust
<b>Dr Teena Mathew</b>	Royal Liverpool University Hospital
<b>Ms Sheila Morris</b>	Western General Hospital, Edinburgh
<b>Dr Chloe Orkin</b>	Barts Health NHS Trust, London
<b>Dr Andrew Riordan</b>	Alder Hey Children's NHS Foundation Trust
<b>Professor Caroline Sabin</b>	University College London
<b>Dr Nicola Steedman</b>	Scottish Executive
<b>Dr Ann Sullivan</b>	Chelsea and Westminster Hospital, London
<b>Dr Craig Tipple</b>	Imperial College Healthcare NHS Trust, London

## BHIVA EXECUTIVE COMMITTEE

### Chair

**Dr D Asboe** Chelsea and Westminster Hospital, London

### Vice Chair

**Dr AJ Palfreeman** Leicester Royal Infirmary

### Honorary Secretary

**Dr A de Ruiter** St Thomas' Hospital, London

### Honorary Treasurer

**Prof C Leen** Western General Hospital, Edinburgh

### TRUSTEES

<b>Dr B Angus</b>	University of Oxford
<b>Prof M Bower</b>	Chelsea and Westminster Hospital, London
<b>Mr G Brough</b>	UK Community Advisory Board
<b>Dr M Chaponda</b>	Royal Liverpool University Hospital
<b>Dr D Churchill</b>	Royal Sussex County Hospital, Brighton
<b>Dr L Dorrell</b>	University of Oxford
<b>Prof MJ Fisher</b>	Brighton and Sussex University Hospitals NHS Trust
<b>Dr AR Freedman</b>	Cardiff University School of Medicine
<b>Prof BG Gazzard</b>	Chelsea and Westminster Hospital, London
<b>Dr RB Kulasegaram</b>	St Thomas' Hospital, London
<b>Dr A Miller</b>	Royal Liverpool University Hospital
<b>Ms S Morris</b>	Western General Hospital, Edinburgh
<b>Dr MR Nelson</b>	Chelsea and Westminster Hospital, London
<b>Prof C Sabin</b>	University College London
<b>Dr A Sullivan</b>	Chelsea and Westminster Hospital, London
<b>Dr M Tenant-Flowers</b>	King's College Hospital NHS Foundation Trust

## BASHH BOARD

### President

**Dr Jan Clarke** Leeds Teaching Hospitals NHS Trust

### Vice President

**Dr Elizabeth Carlin** Nottingham University Hospitals NHS Trust

### Treasurer

**Prof Jonathan Ross** University Hospitals Birmingham NHS Trust

### General Secretary

**Dr Elizabeth Foley** Royal South Hants Hospital, Southampton

### TRUSTEES

<b>Dr Alan Tang</b>	Royal Berkshire NHS Foundation Trust, Reading
<b>Dr Daniel Richardson</b>	Brighton & Sussex University Hospitals NHS Trust
<b>Dr Liat Sarner</b>	Barts Health NHS Trust, London
<b>Dr Cecilia Priestly</b>	Dorset County Hospital NHS Foundation Trust
<b>Dr Jillian Pritchard</b>	Ashford and St Peter's Hospitals NHS Trust, Surrey
<b>Dr Sris Allan</b>	Coventry and Warwickshire Hospital
<b>Dr Nneka Nwokolo</b>	Chelsea and Westminster Hospital, London
<b>Dr Alan McOwan</b>	Chelsea and Westminster Hospital, London
<b>Mr David Roberts-Jones</b>	Lay Trustee
<b>Dr Emily Lord</b>	Churchill Hospital, Oxford
<b>Ms Ceri Evans</b>	Chelsea and Westminster Hospital, London
<b>Mr Colin Roberts</b>	Chelsea and Westminster Hospital, London
<b>Dr John Lee</b>	King Street Health Centre, Wakefield
<b>Mr Peter Greenhouse</b>	United Hospitals Bristol NHS Foundation Trust
<b>Dr Immy Ahmed</b>	Nottingham University Hospitals NHS Trust
<b>Dr Martyn Wood</b>	Mid Cheshire Hospitals NHS Foundation Trust
<b>Dr Janet Wilson</b>	Leeds Teaching Hospitals NHS Trust

# PROGRAMME SUMMARY

## TUESDAY 1 APRIL 2014

1300–1330	Registration open at Arena and Convention Centre Liverpool (New Consultants Forum Only)
1330–1600	New Consultants Forum
1615–2030	Registration open at Arena and Convention Centre Liverpool (BHIVA / BASHH Conference)
1650–1700	Welcome Addresses
1700–1800	Bristol-Myers Squibb Pharmaceuticals Satellite Symposium
1800–1900	Janssen Satellite Symposium
1900–1930	BHIVA / BASHH Keynote Lecture
1930–2030	Welcome Reception: ACC Liverpool
2030–2215	ViiV Healthcare UK Evening Seminar

## WEDNESDAY 2 APRIL 2014

0800–1900	Registration and Exhibition open at Arena and Convention Centre Liverpool
0900–1000	BD Diagnostics Satellite Symposium
1000–1100	AbbVie Ltd Satellite Symposium
1100–1120	Morning coffee
1120–1220	Gilead Sciences Satellite Symposium
1220–1300	BHIVA / BASHH Review Session
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA / BASHH Lunchtime Workshops 1, 2 and 3
1355–1455	Sponsors' Lunchtime Workshops
1500–1630	Oral Research Presentations: Session 1
1630–1700	Afternoon tea
1700–1800	BHIVA / BASHH Plenary Session 1
1800–1900	MSD Ltd Satellite Symposium
1915–2000	Civic Reception: Matou Restaurant

## THURSDAY 3 APRIL 2014

0745–1830	Registration and Exhibition open at Arena and Convention Centre Liverpool
0800–0855	Launch of National Proforma to identify CSE in sexual health services
0900–1000	ViiV Healthcare UK Satellite Symposium
1000–1110	BHIVA / BASHH Plenary Session 2
1110–1135	Morning coffee
1135–1200	Parallel Sessions: MRC Clinical Trials Unit / NATSAL Sessions
1200–1300	Parallel Sessions: Oral Research Presentations: Sessions 2 and 3
1300–1500	Lunch, Workshops and Poster Presentations
1310–1355	BHIVA / BASHH Lunchtime Workshops 4, 5 and 6
1355–1455	Sponsors' Lunchtime Workshops
1500–1630	Parallel Sessions: Oral Research Presentations: Sessions 4 and 5
1630–1700	Afternoon tea
1700–1720	BHIVA / BASHH Audit Session
1720–1820	BHIVA / BASHH Plenary Session 3
2000–0030	Gala Dinner: St George's Hall

## FRIDAY 4 APRIL 2014

0800–1430	Registration and Exhibition open at Arena and Convention Centre Liverpool
0900–1000	Bristol-Myers Squibb Pharmaceuticals Satellite Symposium
1000–1030	BHIVA / BASHH Invited Lecture
1030–1100	Morning coffee
1100–1200	Oral Research Presentations: Session 6
1200–1230	Oral Research Poster Presentations
1230–1430	Lunch, Workshops and Poster Presentations
1240–1325	BHIVA / BASHH Lunchtime Workshops 7, 8 and 9
1325–1425	Sponsors' Lunchtime Workshops
1430–1445	BHIVA / BASHH Prizes and Awards Ceremony
1445–1535	BHIVA / BASHH Plenary Session 4
1535–1615	BHIVA / BASHH Plenary Session 5
1615	Close

# PROGRAMME

## TUESDAY 1 APRIL 2014

1300	<b>Registration open (BHIVA / BASHH New Consultants Forum only)</b>
1330–1600	<b>BHIVA / BASHH New Consultants Forum Room 11C, Upper Level</b> (please see page 27 for further details)
1330–1340	<b>Welcome</b> Chairs: Dr Mas Chaponda <i>Royal Liverpool University Hospital</i> Dr Emma Fox <i>Kent and Canterbury Hospitals NHS Trust</i>
1340–1415	<b>Getting published and improving your publication potential</b> Dr John White <i>Guy's &amp; St Thomas' NHS Foundation Trust, London</i>
1415–1450	<b>Making the most of opportunities to help career progression</b> Professor Jane Anderson <i>Homerton University Hospital, London</i>
1450–1525	<b>BASHH / BHIVA Mentoring Scheme</b> Dr Carol Emerson <i>The Royal Hospitals, Belfast</i>
1525–1600	<b>Setting up a new service</b> Dr Michael Rayment <i>Homerton University Hospital, London</i>
1600	<b>Close</b>
1615–2030	<b>Registration and exhibition open at ACC Liverpool</b>
<b>◀ All sessions will be held in Hall 1A unless otherwise stated ▶</b>	
1650–1700	<b>Welcome Addresses</b> Dr David Asboe <i>Chair, British HIV Association (BHIVA)</i> Dr Jan Clarke <i>President, British Association for Sexual Health and HIV (BASHH)</i>
1700–1800	<b>Bristol-Myers Squibb Pharmaceuticals Satellite Symposium</b> (please see page 20 for further details)
1800–1900	<b>Janssen Satellite Symposium</b> (please see page 20 for further details)
1900–1930	<b>BHIVA / BASHH Keynote Lecture</b> Chair: Professor Sheena McCormack <i>MRC Clinical Trials Unit at UCL, London</i>  <b>21st century prevention: vaccines for sexually transmitted infections, hepatitis and HIV</b> Professor Jonathan Weber <i>Imperial College London</i>
1930–2030	<b>Welcome Reception</b> <b>Hall 1A, Arena and Convention Centre Liverpool</b> (please see page 30 for further details) Chair: Dr Mark Lawton <i>Royal Liverpool University Hospital</i> Dr Alastair Miller <i>British HIV Association (BHIVA) Conference Subcommittee Chair</i> Dr Daniel Richardson <i>British Association for Sexual Health and HIV (BASHH) Conferences and Communications Secretary</i> <i>Drinks and canapés to be served in Hall 2, Lower Level, following speeches</i>
2030–2215	<b>ViiV Healthcare UK Evening Seminar Hall 2N, Lower Level</b> <i>A light buffet supper will be provided. (please see page 20 for further details)</i>

# PROGRAMME

## WEDNESDAY 2 APRIL 2014

0800–1900

Registration and exhibition open at ACC Liverpool

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

0900–1000

**BD Diagnostics Satellite Symposium** (please see page 21 for further details)

1000–1100

**AbbVie Ltd Satellite Symposium** (please see page 21 for further details)

1100–1120

Morning Coffee

1120–1220

**Gilead Sciences Satellite Symposium** (please see page 21 for further details)

1220–1300

**BHIVA / BASHH Review Session**

Chairs: Professor Jonathan Ross

*University Hospitals Birmingham NHS Trust*

Dr Melinda Tenant-Flowers

*King's College Hospital NHS Foundation Trust, London*

**Translating recent research into clinical practice**

Dr John White

*Guy's & St Thomas' NHS Foundation Trust, London*

Dr Laura Waters

*University College London Medical School*

1300–1500

Lunch, Workshops and Poster Presentations

1310–1355

**BHIVA / BASHH Lunchtime Workshop 1 Hall 1A, Upper Level** (please see page 27 for further details)

**Clinico-pathological SpR Case Presentations**

Chair: Professor Sebastian Lucas

*St Thomas' Hospital, London*

**An unusual cause of cystitis in an HIV-positive patient**

Dr Jemy Thomas

*Countess of Chester Hospital*

**Co-existing pathologies and anaemia in an HIV-infected returning traveller**

Dr Dimitra Peppas

*Mortimer Market Centre, London*

**The Clone Wars**

Dr Jake Bayley

*King's College Hospital, London*

1310–1355

**BHIVA / BASHH Lunchtime Workshop 2 Room 4A, Upper Level**

*Lunch packs will be provided* (See page 27 for further details)

Chair: Dr Mas Chaponda

*Royal Liverpool University Hospital*

**Simplifying Antiretroviral Therapy (ART)**

Dr Alastair Miller

*Royal Liverpool University Hospital*

1310–1355

**BHIVA / BASHH Lunchtime Skills Workshop 3 Room 11C, Upper Level**

*Lunch packs will be provided* (See page 27 for further details)

Chair: Ms Sheila Morris

*Western General Hospital, Edinburgh*

**HIV in later life: impact on mental health**

Dr Ravneet Batra

*Western General Hospital, Edinburgh*

Dr Dana Rosenfeld

*Keele University, Newcastle-under-Lyme*



# PROGRAMME

## WEDNESDAY 2 APRIL 2014

- 1355–1455** **Bristol-Myers Squibb Pharmaceuticals Lunchtime Workshop** Room 11B, Upper Level  
(please see page 22 for further details)
- 1355–1455** **Janssen Lunchtime Workshop** Room 4B, Upper Level (please see page 22 for further details)
- 1355–1455** **ViiV Healthcare Lunchtime Workshop** Room 11A, Upper Level (please see page 22 for further details)
- 1500–1630** **Oral Research Presentations: Session 1**  
**Antiretroviral therapy and its complications**  
*Chair: Professor Clifford Leen*  
*Western General Hospital, Edinburgh*  
*Dr Janet Wilson*  
*Leeds Teaching Hospitals NHS Trust*
- 1500–1510 Abstract O1**  
The Protease Inhibitor Versus Ongoing Triple-therapy (PIVOT) trial  
*Professor Nicholas Paton, MRC Clinical Trials Unit at UCL, London*
- 1510–1520 Abstract O2**  
Attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: Week 24 analysis  
*Dr Max Lataillade, Bristol-Myers Squibb Pharmaceuticals*
- 1520–1530 Abstract O3**  
How would health care professionals (HCP) who care for HIV patients treat themselves or a family member if they were HIV+?  
*Dr Laura Waters, Mortimer Market Centre, London*
- 1530–1540 Abstract O4**  
Multicenter open-label study of switching from Atripla to Eviplera for CNS toxicity  
*Miss Jane Rowlands, Chelsea and Westminster Hospital, London*
- 1540–1550 Abstract O5**  
Variation in mode of delivery for HIV-positive women in UK & Irish hospitals, 2008–2013  
*Miss Helen Peters, University College London Institute of Child Health*
- 1550–1600 Abstract O6**  
The clinical utility of therapeutic drug level monitoring of Atazanavir and Darunavir in pregnancy  
*Dr Margaret Kingston, Manchester Royal Infirmary*
- 1600–1610 Abstract O7**  
Recommendation for the off-licence use of maraviroc in children with perinatally acquired HIV-1 infection by a regional paediatric virtual clinic  
*Dr Caroline Foster, Imperial College Healthcare NHS Trust, London*
- 1610–1620 Abstract O8**  
Temporal trends in cART initiation amongst HIV seroconverters in the UK  
*Mrs Victoria Parsons, University College London*
- 1620–1630 Abstract O9**  
HIV and health-related quality-of-life in the UK – where are we now?  
*Dr Alec Miners, London School of Hygiene and Tropical Medicine*
- 1630–1700** Afternoon Tea



## PROGRAMME

### WEDNESDAY 2 APRIL 2014

1700–1800

**BHIVA / BASHH Plenary Session 1: Clinical topics**

**Chairs:** Dr Duncan Churchill

*Brighton and Sussex University Hospitals NHS Trust*

Dr Fiona Lyons

*St James's Hospital, Dublin, Ireland*

**Cardiovascular disease: risk assessment, risk reduction**

Dr James Coutts

*St Thomas' Hospital, London*

**Management of sustained low level viraemia**

Professor Anna Maria Geretti

*Institute of Infection & Global Health, University of Liverpool*

**Enteric infections in men who have sex with men**

Professor Brian Gazzard

*Chelsea and Westminster Hospital, London*

1800–1900

**MSD Ltd Satellite Symposium** (please see page 22 for further details)

1915–2030

**Civic Reception**

**Matou Restaurant** (please see page 30 for further details)

**Chairs:** Dr Alastair Miller

*British HIV Association (BHIVA) Conferences Subcommittee Chair*

Dr Daniel Richardson

*British Association for Sexual Health and HIV (BASHH) Conferences Secretary*

Councillor Gary Millar

*The Right Worshipful, The Lord Mayor of the City of Liverpool*

Dr David Asboe

*Chair, British HIV Association (BHIVA)*

Dr Jan Clarke

*President, British Association for Sexual Health and HIV (BASHH)*

# PROGRAMME

## THURSDAY 3 APRIL 2014

0745–1820

Registration desk and exhibition open at ACC Liverpool

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

0800–0855

**Launch of National Proforma to identify child sexual exploitation (CSE) in sexual health services** Room 4A, Upper Level *(please see page 23 for further details)*

0900–1000

**ViiV Healthcare Satellite Symposium** *(please see page 23 for further details)*

1000–1110

**BHIVA / BASHH Plenary Session 2: Clinical and community practice**

**Chair:** Mr Garry Brough

*UK Community Advisory Board (UK-CAB)*

**Dr Margaret Kingston**

*Central Manchester University Hospitals NHS Foundation Trust*

**Strategies for retaining people living with HIV in care**

**Dr Vanessa Apea**

*Barts Health NHS Trust, London*

**Ms Eileen Nixon**

*Brighton and Sussex University Hospitals NHS Trust*

**HIV testing: new technologies and new strategies for those at higher risk**

**Dr Alan McOwan**

*Chelsea and Westminster Hospital, London*

**Partner notification for HIV: maximising positive outcomes**

**Dr Ann Sullivan**

*Chelsea and Westminster Hospital, London*

1110–1135

Morning Coffee

1135–1300

**Parallel Sessions**

**Note:** The MRC and NATSAL sessions and Oral Research Presentation Sessions 2 and 3 will run in parallel. Please check the location of these Sessions carefully

1135–1200

**MRC Clinical Trials Unit Session** Room 11, Upper Level

**Chair:** Professor Martin Fisher

*Brighton and Sussex University Hospitals NHS Trust*

**Protease inhibitors: what's the best companion?**

**Professor Nick Paton**

*MRC Clinical Trials Unit at UCL, London*

**Professor Abdel Babiker**

*MRC Clinical Trials Unit at UCL, London*

1135–1200

**National Survey of Sexual Attitudes and Lifestyle (NATSAL) Session** Hall 1A, Upper Level

**Chair:** Dr John White

*St Thomas' Hospital, London*

**Professor Anne Johnson**

*UCL Institute of Epidemiology and Health Care, London*

THURSDAY 3 APRIL 2014

1200–1300

**Oral Research Presentations: Session 2 Room 11, Upper Level**

**Basic science and immunology**

**Chairs:** Professor Mark Bower

*Chelsea and Westminster Hospital, London*

Dr Elizabeth Foley

*Royal South Hants Hospital*

**1200–1210 Abstract O10**

Evaluation of circulating gut-homing T cells as a marker of HIV-1 progression and immune reconstitution

*Dr Lucy Dorrell, University of Oxford*

**1210–1220 Abstract O11**

Beneficial effect of NNRTI over boosted PI first line cART on CD4 T-cell restoration in older HIV-1+ patients

*Dr Anna Herasimtschuk, Imperial College London*

**1220–1230 Abstract O12**

Protection versus pathology in aviremic and high viral load HIV-2 infection – the pivotal role of immune activation and T-cell kinetics

*Professor Derek Macallan, St George's, University of London*

**1230–1240 Abstract O13**

IP-10 levels in HIV/HCV co-infection decrease with the initiation of successful antiretroviral (ART) therapy: Implications for earlier ART in co-infected patients?

*Dr Kate Childs, King's College Hospital NHS Foundation Trust, London*

**1240–1250 Abstract O14**

The effect of HCV infection duration on HIV disease progression

*Mr Jamie Inshaw, University College London*

**1250–1300 Abstract O15**

Immunological efficacy of a prime-boost vaccine strategy combining the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) versus PPV 23 alone in HIV-infected adults

*Dr Corinna Sadlier, St James's Hospital, Dublin, Ireland*

1200–1300

**Oral Research Presentations: Session 3 Hall 1A, Upper Level**

**Service delivery**

**Chairs:** Professor Christopher Fairley

*The University of Melbourne, Australia*

Dr Adrian Palfreman

*Leicester Royal Infirmary*

**1200–1210 Abstract O16**

Less is more: The impact of a new senior model on clinic throughput and its ability to support staff to reach their full potential

*Dr Anatole Menon-Johansson, Guy's & St Thomas' NHS Foundation Trust, London*

**1210–1220 Abstract O17**

ePN: electronic partner notification is an effective, efficient method to deliver partner notification and capture verified outcomes

*Dr Ann Sullivan, Chelsea and Westminster Hospital, London*

**1220–1230 Abstract O18**

Active recall for HIV/STI testing: a systematic review

*Dr Monica Desai, Public Health England*

# PROGRAMME

## THURSDAY 3 APRIL 2014

### 1230–1240 Abstract O19

Patients' referral pathway in the first year of HIV care  
*Dr Zheng Yin, Public Health England*

### 1240–1250 Abstract O20

Trends in HIV testing outside of traditional services  
*Ms Sarah Collins, Public Health England*

### 1250–1300 Abstract O21

Home HIV sampling linked to national HIV testing campaigns: a novel approach to improve HIV diagnosis  
*Dr Michael Brady, Terrence Higgins Trust*

1300–1500

Lunch, Workshops and Poster Presentations

1310–1355

**BHIVA / BASHH Lunchtime Workshop 4 Hall 1A, Upper Level** (please see page 27 for further details)

**Legal responses to HIV & other STIs: professional obligations, medical ethics and public health**  
**Dr Mark Lawton**  
*Royal Liverpool University Hospital*

**Professor Matthew Weait**  
*Birkbeck, University of London*

1310–1355

**BHIVA / BASHH Lunchtime Workshop 5 Room 11, Upper Level**

*Lunch packs will be provided (See page 27 for further details)*

**Pregnancy, breastfeeding and HIV: Experience and case presentations**

**Chair: Dr Annemiek de Ruiter**  
*St Thomas' Hospital, London*

*Panel*

**Dr Fiona Lyons**  
*St James's Hospital, Dublin, Ireland*

**Dr Andrew Riordan**  
*Alder Hey Children's NHS Foundation Trust, Liverpool*

### Third trimester conundrum

**Dr Subathira Dakshina**  
*Barts Health NHS Trust*

### The challenges of adherence during pregnancy

**Dr Olivia Drew**  
*Solent NHS Trust*

### Clinical dilemmas in supporting women living with HIV to breastfeed

**Ms Emma Macfarlane**  
*Barking, Havering and Redbridge University Hospitals NHS Trust*

1310–1355

**BHIVA / BASHH Lunchtime Skills Workshop 6 Room 13, Upper Level**

*Lunch packs will be provided (See page 27 for further details)*

**Chair: Dr Michael Brady**  
*King's College Hospital NHS Foundation Trust, London*

### Preventing sexually transmitted infection re-infection

**Dr Claudia Estcourt**  
*Barts and the London School of Medicine and Dentistry*

1355–1455

**Cepheid Lunchtime Workshop Room 4B, Upper Level** (please see page 24 for further details)

1355–1455

**Janssen Lunchtime Workshop Room 4A, Upper Level** (please see page 24 for further details)



# PROGRAMME

## THURSDAY 3 APRIL 2014

1500–1630

### Parallel Sessions

**Note:** Oral Research Presentation Sessions 4 and 5 will run in parallel. Please check the location of these Sessions carefully

1500–1630

### Oral Research Presentations: Session 4 Room 11, Upper Level

#### Complications and co-morbidities

**Chairs:** Dr Daniel Richardson

*Brighton and Sussex University Hospitals NHS Trust*

Professor Caroline Sabin

*University College London*

#### 1500–1510 Abstract O22

A hepatitis C virus core antigen assay is a cost-effective, sensitive and specific test in the detection of acute hepatitis C infection in HIV-infected subjects

*Mr Robert Carney, Royal Free London NHS Foundation Trust*

#### 1510–1520 Abstract O23

Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-positive men with acute HCV

*Dr Daniel Bradshaw, Kirby Institute, University of New South Wales Sydney, Australia*

#### 1520–1530 Abstract O24

Second malignancies in patients with Kaposi's sarcoma (KS): Does systemic chemotherapy contribute to the risk?

*Miss Maggie Smith, Chelsea and Westminster Hospital, London*

#### 1530–1540 Abstract O25

End-stage kidney disease and kidney transplantation in HIV-positive patients in the UK Collaborative HIV Cohort (CHIC) Study

*Ms Sophie Jose, University College London*

#### 1540–1550 Abstract O26

Management of cardiovascular risk in HIV-positive individuals in Europe

*Dr Maryam Shahmanesh, University College London*

#### 1550–1600 Abstract O27

Disease burden due non-chronic viral hepatitis-related liver disease in HIV-positive individuals: preliminary results from a longitudinal cohort study

*Dr Natalie Shur, The Royal Sussex County Hospital, Brighton*

#### 1600–1610 Abstract O28

Attitude of HIV patients towards organ transplant between HIV patients

*Dr Huda Taha, Coventry and Warwickshire Partnership Trust*

#### 1610–1620 Abstract O29

Facilitating self-care in HIV with digital patient-controlled health records

*Dr Zoe Warwick, Plymouth Hospitals NHS Trust*

#### 1620–1630 Abstract O30

Validation of the rationalisation of routine blood tests and visits for HIV-1-infected individuals

*Dr Alastair Teague, Guy's & St Thomas' NHS Foundation Trust, London*

1500–1630

### Oral Research Presentations: Session 5 Hall 1A, Upper Level

#### Sexually transmitted infections

**Chairs:** Dr Gillian Dean

*Brighton and Sussex University Hospitals NHS Trust*

Dr Alastair Miller

*Royal Liverpool University Hospital*

# PROGRAMME

## THURSDAY 3 APRIL 2014

### 1500–1510 Abstract O31

The epidemiology of *Mycoplasma genitalium* in the British population: Findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)

*Dr Pam Sonnenberg, University College London*

### 1510–1520 Abstract O32

The prevalence of *Mycoplasma genitalium* among male GUM attendees using an in-house PCR on BD Max platform

*Ms Rebecca Slack, Sheffield Teaching Hospitals*

### 1520–1530 Abstract O33

Human papillomavirus infection and cervical cancer prevention in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)

*Dr Clare Tanton, University College London*

### 1530–1540 Abstract O34

Feasibility and acceptability of a quadrivalent human papillomavirus vaccination programme (HPV4) for young men who have sex with men (MSM) within a comprehensive sexually transmitted infection (STI) testing and sexual health engagement strategy: Results from the first year

*Dr John McSorley, North West London Hospitals NHS Trust*

### 1540–1550 Abstract O35

High-risk drug practices associated with *Shigella flexneri* serotype 3a infections amongst men who have sex with men (MSM) in England

*Ms Victoria Gilbert, Public Health England*

### 1550–1600 Abstract O36

Gastroenterology out-patient clinic: rectal pain and discharge associated with a history of receptive anal sex in women

*Dr Sarah Allstaff, NHS Tayside, Scotland*

### 1600–1610 Abstract O37

Highly diverse genotypes of rectal *Chlamydia trachomatis*, using multi-locus VNTR analysis (MLVA)-ompA sequencing, among men who have sex with men (MSM) attending a GUM clinic

*Dr Judith Zhou, Brighton and Sussex University Hospitals NHS Trust*

### 1610–1620 Abstract O38

Performance of ceftriaxone 500mg-containing regimens for treatment of genital and extra-genital gonorrhoea

*Dr Selena Singh, Guy's & St Thomas' NHS Foundation Trust, London*

### 1620–1630 Abstract O39

Detection of HIV-1 viral load in the rectum

*Dr Julie Fox, Guy's & St Thomas' NHS Foundation Trust, London*

1630–1700

Afternoon Tea

1700–1720

**BHIVA / BASHH Audit Session**

**Chairs:** Dr Andrew Freedman

*Cardiff University School of Medicine*

Dr Hugo McClean

*City Health Care Partnership Hull*

**BASHH national audit on the management of anogenital herpes**

Dr Anatole Menon-Johansson

*Guy's & St Thomas' NHS Foundation Trust, London*

## PROGRAMME

### THURSDAY 3 APRIL 2014

1720–1820

**BHIVA / BASHH Plenary Session 3: The virtual clinic**

**Chairs:** Professor Brian Angus

*University of Oxford*

Dr David Phillips

*Croydon University Hospital*

**Managing men with *M. genitalium* urethritis**

Professor Jonathan Ross

*University Hospitals Birmingham NHS Trust*

**Investigating pyrexia of unknown origin**

Dr Andy Ustianowski

*North Manchester General Hospital*

**Safeguarding and sexual health in HIV**

Ms Linda Furness

*Cardiff Royal Infirmary*

2000–0030

**Gala Dinner** (please see page 30 for further details)

**St George's Hall**

# PROGRAMME

## FRIDAY 4 APRIL 2014

0800–1430

Registration desk and exhibition open at ACC Liverpool

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

0900–1000

**Bristol-Myers Squibb Pharmaceuticals Satellite Symposium** (please see page 25 for further details)

1000–1030

**BHIVA / BASHH Invited Lecture**

**Chair:** Dr Leena Sathia

*Royal Free Hampstead NHS Trust, London*

**Syphilis: immunology and HIV**

**Professor Christina Marra**

*University of Washington School of Medicine, USA*

1030–1100

Morning Coffee

1100–1200

**Oral Research Presentations: Session 6**

**Lifestyle and HIV Transmission**

**Chairs:** Dr Lucy Dorrell

*University of Oxford*

**Dr Alan McOwan**

*Chelsea and Westminster Hospital, London*

**1100–1110 Abstract O40**

**Sex, drugs and STIs**

*Dr Nadia Ekong, Leeds Centre for Sexual Health*

**1110–1120 Abstract O41**

**High levels of recreational drug use (RDU) in HIV clinics - concerns for onward HIV transmission and adherence with treatment**

*Dr Selena Singh, Guy's & St Thomas' NHS Foundation Trust, London*

**1120–1130 Abstract O42**

**Psychological interventions to reduce sexual risk-taking**

*Dr Dorota Jagielska-Hall, Homerton University Hospital, London*

**1130–1140 Abstract O43**

**Who accesses PrEP? An analysis of baseline data in the PROUD pilot**

*Dr Monica Desai, Public Health England*

**1140–1150 Abstract O44**

**Understanding the acceptability of pre-exposure prophylaxis (PrEP) for HIV prevention amongst gay and bisexual men in Scotland: a mixed methods study**

*Dr Jamie Frankis, Glasgow Caledonian University*

**1150–1200 Abstract O45**

**Acute Hepatitis C in the PROUD pilot study**

*Dr Juan Tiraboschi, Guy's & St Thomas' NHS Foundation Trust, London*

1200–1230

**Oral Research Poster Presentations**

**Chairs:** Dr Carol Emerson

*The Royal Hospitals, Belfast*

**Dr Danielle Mercey**

*Central & North West London NHS Foundation Trust*

1230–1430

Lunch, Workshops and Poster Presentations



FRIDAY 4 APRIL 2014

1240–1325

**BHIVA / BASHH Lunchtime Workshop 7 Hall 1A, Upper Level** (please see page 27 for further details)

**Chair:** Dr Simon Barton

*Chelsea and Westminster Hospital, London*

**BHIVA / BASHH Commissioning workshop: members' report on challenges and opportunities**

**Dr David Asboe**

*Chelsea and Westminster Hospital, London*

**Dr Janet Wilson**

*Leeds Teaching Hospitals NHS Trust*

**Ms Kate Folkard**

*Public Health England*

1240–1325

**BHIVA / BASHH Lunchtime Workshop 8 Room 11B, Upper Level**

*Lunch packs will be provided (See page 27 for further details)*

**Polypharmacy and shared care issues: bridging primary and secondary care systems**

**Chair:** Mr Ben Cromorty

*North Yorkshire AIDS Action*

**Professor Saye Khoo**

*University of Liverpool*

1240–1325

**BHIVA / BASHH Lunchtime Skills Workshop 9 Room 11C, Upper Level**

*Lunch packs will be provided (See page 27 for further details)*

**Benefits of international exchange scholarships: looking back, looking ahead**

**Chair:** Dr Sanjay Bhagani

*Royal Free Hospital, London*

**Ms Dola Awoyemi**

*Kingston Hospital, London*

**Dr Analía Urueña**

*Helios Salud, Buenos Aires, Argentina*

**Dr Subathira Dakshina**

*Barts Health NHS Trust, London*

**Dr Alexandra Clarissa Teleka**

*Blantyre District Health Office, Malawi*

**Panel:**

**Dr Ranjababu Kulasegaram**

*St Thomas' Hospital, London*

1325–1425

**Gilead Sciences Lunchtime Workshop Room 4A, Upper Level** (please see page 25 for further details)

1325–1425

**ViiV Healthcare Lunchtime Workshop Room 4B, Upper Level** (please see page 25 for further details)

FRIDAY 4 APRIL 2014

1325–1425

**BHIVA / BASHH Lunchtime Workshop 10 Room 11A, Upper Level** (please see page 27 for further details)

**Managing the complexities of pharmacology in HIV / hepatitis C co-infected patients**

Professor David Back

*University of Liverpool*

Professor Massimo Puoti

*Niguarda Ca Granda Hospital, Milan, Italy*

*BHIVA is grateful for an educational grant in support of this workshop from Boehringer Ingelheim*

*Please see page 27 for further details*

1430–1445

**BHIVA / BASHH Prizes and Awards Ceremony**

1445–1535

**BHIVA / BASHH Plenary Session 4**

**Chairs:** Dr Paddy Horner

*University of Bristol*

Dr Ranjababu Kulasegaram

*St Thomas' Hospital, London*

**HPV vaccination in men who have sex with men**

Professor Christopher Fairley

*The University of Melbourne, Australia*

**Hepatitis C: when to treat and when to wait**

Professor Massimo Puoti

*Niguarda Ca Granda Hospital, Milan, Italy*

1535–1615

**BHIVA / BASHH Plenary Session 5**

**Chairs:** Dr David Asboe

*Chelsea and Westminster Hospital, London*

Dr Mette Rodgers

*Croydon University Hospital*

**Chem-sex: Why is it problematic and what can we do about it?**

Dr Ann Sullivan

*Chelsea and Westminster Hospital, London*

Dr Adam Winstock

*King's College Hospital, London*

1615

**Close**

Dr David Asboe

*Chair, British HIV Association (BHIVA)*

Dr Jan Clarke

*President, British Association for Sexual Health and HIV (BASHH)*

“LIFE’S A JOURNEY.  
I’M IN IT FOR THE LONG TERM.”



**KALETRA®**  
(lopinavir/ritonavir)

Protection tomorrow, starts today

The HIV-positive population in the UK is ageing,<sup>1</sup>  
bringing a greater incidence of co-morbidities vs.  
HIV-negative patients<sup>2</sup>

Kaletra has been proven to

- Treat an ageing treatment-experienced population<sup>3</sup>
- Deliver 7-year virological efficacy with CD4 increases in ARV-naïve patients<sup>4</sup>
- Demonstrate similar efficacy in women and men at 48 weeks<sup>5</sup>

abbvie

**Kaletra® (lopinavir/ritonavir)** See summary of characteristics prior to prescribing. **PRESENTATION:** Oral Solution: 1 ml contains 80 mg lopinavir and 20 mg ritonavir. 100mg/25mg film-coated tablets: 100 mg lopinavir and 25 mg ritonavir. 200mg/50mg film-coated tablets: 200 mg lopinavir and 50 mg ritonavir. **INDICATION:** Antiretroviral in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents and children over 2 years. **DOSAGE AND ADMINISTRATION: Adults & Adolescents:** Oral Solution: 5 ml (400/100mg) twice daily with food. Film-coated tablets: Standard recommended dosage is 400/100 mg (two 200/50 mg tablets or four 100/25 mg tablets) twice daily with or without food. May be administered as 800/200 mg (four 200/50 mg tablets) once daily with or without food, where appropriate. Once daily dosing should be limited to those adult patients having <3 protease inhibitor (PI) associated mutations (in line with clinical trial results) and should take into account the risk of a lesser sustainability of the virologic suppression and higher risk of diarrhoea compared to the recommended standard twice daily dosing. See SmPC for full details. **Children over 2 years:** Oral Solution: 230/57.5 mg/m<sup>2</sup> twice daily with food. Maximum dose 400/100 mg twice daily. For weight-based dosing, of patients ≥ 15 to 40 kg, 10/2.5 mg/kg twice daily is recommended. An increase to 300/75 mg/m<sup>2</sup> twice daily should be considered when co-administered with nevirapine or efavirenz. 200/50 mg film-coated tablets: Children over 40 kg with a BSA ≥ 1.4 m<sup>2</sup> and able to swallow tablets may take 2 tablets twice daily with or without food. 100/25 mg film-coated tablets: Children under 40 kg or with a BSA between 0.5 and 1.4 m<sup>2</sup> use following doses: BSA ≥ 0.5 to <0.9 m<sup>2</sup> (15 to 25kg), 2 tablets twice daily. BSA ≥ 0.9 to <1.4 m<sup>2</sup> (> 25 to 35kg), 3 tablets twice daily. BSA ≥ 1.4 m<sup>2</sup> (> 35kg), 4 tablets twice daily. Concomitant therapy with efavirenz or nevirapine: BSA ≥ 0.5 to <0.8 m<sup>2</sup>, 2 tablets twice daily. BSA ≥ 0.8 to <1.2, 3 tablets twice daily. BSA ≥ 1.2 to <1.4, 4 tablets twice daily. BSA ≥ 1.4 m<sup>2</sup>, 5 tablets twice daily. For convenience 200/50 mg and 100/25 mg tablets may be combined to achieve the recommended dose. Once daily dosing has not been evaluated in paediatrics. **CONTRAINDICATIONS:** Hypersensitivity to lopinavir, ritonavir or any excipient. Severe hepatic insufficiency. Do not co-administer with medicinal products highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events, including alfuizosin, amiodarone, fusidic acid, astemizole, terfenadine, pimozide, quetiapine, ergot alkaloids, cisapride, lovastatin, simvastatin, avanafil, vardenafil, sildenafil in treatment of pulmonary arterial hypertension, oral midazolam and triazolam. Co-administration with St John's Wort. Oral Solution is contraindicated in children under 2 years, pregnant women, patients with hepatic or renal failure and patients treated with disulfiram or metronidazole due to risk of toxicity from exipient propylene glycol. **SPECIAL WARNINGS AND PRECAUTIONS:** Patients with chronic hepatitis B or C treated with combination antiretroviral therapy (CART) are at increased risk for severe and potentially fatal hepatic adverse reactions. Patients with pre-existing liver dysfunction should be monitored. If evidence of worsening liver disease, consider interruption/discontinuation of treatment. Haemophilic patients at risk of increased bleeding. Cases of pancreatitis have been reported. New onset or exacerbation of existing diabetes mellitus has been reported. CART has been associated with lipodystrophy and metabolic abnormalities. Immune reactivation syndrome may occur, especially in patients with severe immune deficiency at initiation of CART. Patients with advanced HIV-disease and/or long-term exposure to CART may develop osteonecrosis. Rare reports of 2<sup>nd</sup> or 3<sup>rd</sup> degree atrioventricular block in patients with underlying structural heart disease and pre-existing conduction system

abnormalities or in patients known to prolong the PR interval. Supratherapeutic doses of Kaletra (800/200mg twice daily) have been shown to increase the QTcF interval. Patients taking oral solution, particularly with renal impairment or inability to metabolise propylene glycol should be monitored for propylene glycol toxicity. Please refer to INTERACTIONS for precautions with other medicinal products. **INTERACTIONS:** See SmPC for full details. Lopinavir and ritonavir are inhibitors of CYP3A and are likely to increase plasma concentrations of products primarily metabolised by CYP3A. Avoid concomitant administration with colchicine, particularly in patients with renal or hepatic impairment. Combination with the following medicinal products is not recommended: tadalafil for treatment of PAH, fusidic acid, salmeterol, rivaroxaban, atorvastatin (unless considered strictly necessary with careful safety monitoring), rifampicin, boceprevir and telaprevir. Exercise caution and consider reduced doses with rosvastatin. If treatment with an HMG-CoA reductase inhibitor is indicated, fluvastatin or pravastatin is recommended. Use caution in co-administration with sildenafil or tadalafil for the treatment of erectile dysfunction. Use caution with medicinal products known to induce QT interval prolongation (e.g. chlorpheniramine, quinidine, erythromycin, clarithromycin). Concomitant administration with glucocorticoids/corticosteroids metabolised via CYP3A (e.g. fluticasone propionate or budesonide) is not recommended unless benefit outweighs the risk of systemic corticosteroid effects. Higher tenofovir concentrations could potentiate associated adverse events, including renal disorders. Dosage may be increased to 500/125 mg twice daily when co-administered with efavirenz and nevirapine. Co-administration with maraviroc requires dose adjustment of Maraviroc (see SmPC). Concomitant use with fosamprenavir or tipranavir is not recommended. Concomitant use with fentanyl requires careful monitoring of adverse events (notably respiratory depression and sedation). Co-administration with digoxin, bepridil, systemic lidocaine and quinidine requires caution and monitoring as concentrations might be increased. Caution in co-administration with clarithromycin to patients with impaired hepatic or renal function. Risk of increased adverse events with most tyrosine kinase inhibitors, requiring careful monitoring. Warfarin concentrations may be affected. Caution and monitoring when administering with carbamazepine, phenobarbital, phenytoin and valproate. Lamotrigine dose adjustment may be required. Use caution with trazodone, a lower dose of trazodone may be considered in combination with Kaletra. High doses of ketoconazole or itraconazole (>200 mg/day) are not recommended. Avoid co-administration with voriconazole unless benefit outweighs the risk of reduced voriconazole levels. Consider dosage adjustment of rifabutin when given with Kaletra. Use extreme caution and ICU monitoring when co-administering with parenteral midazolam. Concomitant use with felodipine, nifedipine and nicardipine requires caution and clinical monitoring. Dexamethasone may decrease lopinavir concentrations. Cyclosporin, sirolimus and tacrolimus concentrations may be increased. Kaletra may lower plasma concentrations of methadone. Alternative/additional contraceptive measures needed when co-administered with oestrogen-based oral contraceptives. Co-administration with bupropion requires close clinical monitoring. Caution should be exercised in administering with bosentan. Kaletra must not be administered once daily in combination with efavirenz, nevirapine, amprenavir, carbamazepine, phenobarbital or phenytoin. **PREGNANCY AND LACTATION:** There are no adequate and well-controlled studies of Kaletra in pregnant women. The prevalence of birth defects after any trimester exposure to lopinavir is comparable to the prevalence observed in the general population. It is not known whether Kaletra (oral solution/tablet) is excreted in human

milk. HIV infected women must not breast-feed their infants under any circumstances to avoid transmission of HIV. **SIDE EFFECTS:** See SmPC for full details on side-effects. In paediatric patients the nature of the safety profile is similar to that seen in adults. **Very common side effects (≥1/10):** upper respiratory tract infection, diarrhoea and nausea. **Common side effects (≥1/100 to <1/10):** Lower respiratory tract infection, skin infections including cellulitis, folliculitis and furuncle, anaemia, leucopenia, neutropenia, lymphadenopathy, hypersensitivity including urticaria and angioedema, blood glucose disorders including diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia, weight decreased, decreased appetite, anxiety, headache (including migraine), neuropathy (including peripheral neuropathy), dizziness, insomnia, hypertension, pancreatitis, vomiting, gastroesophageal reflux disease, gastroenteritis and colitis, abdominal pain (upper and lower), abdominal distension, dyspepsia, haemorrhoids, flatulence, hepatitis including AST, ALT and GGT increases, lipodystrophy including facial wasting, rash including maculopapular rash, dermatitis/rash including eczema and seborrheic dermatitis, night sweats, pruritus, myalgia, musculoskeletal pain including arthralgia and back pain, muscle disorders such as weakness and spasms, erectile dysfunction, menstrual disorders – amenorrhoea, menorrhagia and fatigue including asthenia. **Potentially serious uncommon side effects (≥ 1/1000 to < 1/100):** immune reactivation syndrome, cerebrovascular accident, convulsion, atherosclerosis such as myocardial infarction, atrioventricular block, tricuspid valve incompetence, deep vein thrombosis, gastrointestinal haemorrhage, hepatomegaly, cholangitis, vasculitis, rhabdomyolysis, osteonecrosis, creatinine clearance decreased and nephritis. Post-marketing surveillance experience (frequency unknown) :- Stevens-Johnson syndrome, erythema multiforme and jaundice. **LEGAL CATEGORY:** POM **MARKETING AUTHORISATION NUMBERS/ PRESENTATIONS/BASIC NHS COST:** Oral Solution: EU/1/01/172/003; 5 bottles of 60ml Cost: £307.39 200mg/50mg film-coated tablets: EU/1/01/172/004; 1 bottle of 120 tablets Cost: £285.41 EU/1/01/172/008; 1 carton of 120 tablets Cost: £285.41 100mg/25mg film-coated tablets: EU/1/01/172/006; 1 Bottle of 60 tablets Cost: £76.85. **MARKETING AUTHORISATION HOLDER:** AbbVie Ltd, Maidenhead, SL6 4XE **DATE OF REVISION:** January 2014 PI/Kaletra/031

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) Adverse events should also be reported to AbbVie Ltd on 01628 774933

**References:** 1. Public Health England. HIV in the United Kingdom: 2013 Report. Available at: [http://www.hpa.org.uk/web/HPAwebFile/HPAweb\\_C/1317140300680](http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1317140300680). Last accessed March 2014. 2. Guaraldi G *et al.* Presented at CROI, February 16–19, 2010; San Francisco, Calif. Poster 0-209. 3. Gaultier IA *et al.* Poster presented at: 12th European AIDS Conference; November 11–14, 2009. Poster PE7.5/3. 4. Murphy R *et al.* Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naïve subjects. 10th European AIDS Conference, November 2005; Dublin, Ireland. Poster PE7.9/3. 5. Hermes A *et al.* Efficacy, safety and tolerability of lopinavir/ritonavir (LPV/r) in HIV-infected women: results of a meta-analysis of 7 prospective, randomized clinical trials (RCTs) through 48 weeks. 1st International Workshop on HIV & Women from Adolescence through Menopause, January 2011; Washington DC, USA.

AXKAL140333. Date of preparation: March 2014.

# SATELLITE SYMPOSIA SEMINARS AND WORKSHOPS

**TUESDAY 1 APRIL 2014**

*All satellite symposia will be held in Hall 1A, Upper Level  
Locations of workshops and evening seminars are listed below adjacent to the respective events*

**1700–1800**

**Bristol-Myers Squibb Pharmaceuticals Satellite Symposium**

**Partnering for HIV cure: The limits of cART**

*Chair: Professor Jonathan Weber  
Imperial College, London*

**A foundation for cure: bridging the gap with cART**

*Dr Mark Nelson  
Chelsea and Westminster Hospital, London*

**Management of primary HIV infection: opportunities and challenges**

*Dr Sarah Fidler  
Imperial College, London*

**1800–1900**

**Janssen Satellite Symposium**

**HIV 2020 vision: focusing on the future of HIV treatment**

**Welcome and introduction**  
*Professor Jane Anderson  
Homerton University Hospital, London*

**Changing the ARV treatment paradigm**  
*Dr Mas Chaponda  
Royal Liverpool Hospitals*

**Moving forward the agenda on HIV cure**  
*Dr John Frater  
University of Oxford*

**Future innovations in medical technology**  
*Dr Bertalan Meskó  
Medical Futurist*

**2030–2215**

**ViiV Healthcare UK Evening Seminar Hall 2N, Lower Level (adjacent to Exhibition Hall)**

*A light buffet supper will be provided. Entrance on a first-come, first-served basis.  
Doors open 10 minutes prior to Seminar.*

**Let's talk: What matters in HIV?**

*Chair: Mr Richard Phillips  
ViiV Healthcare UK*

**Professor Brian Gazzard**  
*Chelsea and Westminster Hospital, London*

**Dr Anton Pozniak**  
*Chelsea and Westminster Hospital, London*

**Dr Julie Fox**  
*Guy's and St Thomas' NHS Foundation Trust, London*

**Dr Yusef Azad**  
*National AIDS Trust*



## SATELLITE SYMPOSIA SEMINARS AND WORKSHOPS

**WEDNESDAY 2 APRIL 2014**

*All satellite symposia will be held in Hall 1A, Upper Level  
Locations of workshops and evening seminars are listed below adjacent to the respective events*

**0900–1000**

**BD Diagnostics Satellite Symposium**

**How to manage *Mycoplasma genitalium* as an STD**

Dr Harald Moi

*University of Oslo, Norway*

**How important is nucleic acid contamination within a sexual health clinic?**

Professor Jonathan Ross

*University Hospitals Birmingham NHS Foundation Trust*

**1000–1100**

**AbbVie Ltd Satellite Symposium**

**Positive ageing with HIV: a patient-centred approach**

Dr Tristan Barber

*Homerton University Hospital, London*

Dr Laura Waters

*Mortimer Market Centre, London*

Mr Robert Fieldhouse

*BASELINE*

Professor Brian Gazzard

*Chelsea and Westminster Hospital, London*

**1120–1220**

**Gilead Sciences Satellite Symposium**

**HIV I got news for you**

**Chair:** Dr Simon Barton

*Chelsea and Westminster Hospital, London*

Dr Andrew Ustianowski

*North Manchester General Hospital*

Dr Colm O'Mahony

*Countess of Chester Hospital NHS Trust, Chester*

Prof Jane Anderson

*Homerton University Hospital, London*

Dr Anton Pozniak

*Chelsea and Westminster Hospital, London*

Dr Karen Rogstad

*Sheffield Teaching Hospitals NHS Foundation Trust*

Dr Mark Lawton

*Royal Liverpool University Hospital*

# SATELLITE SYMPOSIA SEMINARS AND WORKSHOPS

## WEDNESDAY 2 APRIL 2014

*All satellite symposia will be held in Hall 1A, Upper Level  
Locations of workshops and evening seminars are listed below adjacent to the respective events*

**1355–1455**

**Bristol-Myers Squibb Lunchtime Workshop** Room 11B, Upper Level  
**Ageing positively: Women with HIV, treatment now and in the future**

**Chair:** Dr Mas Chaponda  
*Royal Liverpool University Hospital*

**Dr Fatima Ibrahim**  
*St. Peter's Health Centre, Leicester*

**Professor Fiona Mulcahy**  
*St James's Hospital, Dublin, Ireland*

**1355–1455**

**Janssen Lunchtime Workshop** Room 4B, Upper Level  
**Unlocking patient potential in HIV management**

**Chair:** Mr Allan Anderson  
*Positively UK*

**Dr Mohammad Al-Ubaydli**  
*Patients Know Best*

**Dr Michael Brady**  
*King's College Hospital, London*

**Mr Paul Decle**  
*Patient Representative, Chelsea and Westminster Hospital*

**1355–1455**

**ViiV Healthcare Lunchtime Workshop** Room 11A, Upper Level  
**Resistance in the current era of HIV Management: clinical challenges**

**Chair:** Professor Anna Maria Geretti  
*University of Liverpool*

**Dr Marta Boffito**  
*Chelsea and Westminster Hospital, London*

**Dr Tomas Doyle**  
*Royal Free Hospital, London*

**1800–1900**

**MSD Ltd Satellite Symposium**  
**HIV: At a Crossroads?**

**Chair:** Dr Andrew Ustianowski  
*North Manchester General Hospital*

**Dr Simon Barton**  
*Chelsea and Westminster Hospital, London*

**Dr Tristan Barber**  
*Homerton University Hospital, London*

**Dr Ed Wilkins**  
*North Manchester General Hospital*



## SATELLITE SYMPOSIA SEMINARS AND WORKSHOPS

**THURSDAY 3 APRIL 2014**

*All satellite symposia will be held in Hall 1A, Upper Level  
Locations of workshops and evening seminars are listed below adjacent to the respective events*

**0800–0855**

**Spotting the signs: a national proforma for identifying risk of child sexual exploitation in sexual health services**

**A Department of Health funded project delivered by British Association of Sexual Health & HIV (BASHH) and Brook Room 4A, Upper Level**

*A light breakfast of Danish pastries and refreshments will be provided.*

**Chairs:** Dr Janet Wilson

*Immediate Past President, British Association for Sexual Health & HIV*

**Mr Simon Blake**

*Chief Executive, Brook*

**Background and context of project**

**Ms Andrea Duncan**

*Department of Health*

**Video Messages**

**Jane Ellison MP**

*Parliamentary Under Secretary of State for Public Health*

**Norman Baker MP**

*Minister of State for Crime Prevention*

**CSE in gangs and groups**

**Ms Claire Manchester**

*Metropolitan Police and London Multiagency Safeguarding Hub*

**Methodology, results of focus groups, pilot results and final proforma**

**Dr Karen Rogstad**

*Chair of BASHH Advisory Board and Working Group*

**Panel Discussion**

**Ms Sarah Doran**

*Greater Manchester Sexual Health Network*

**Mr Duy Hoang**

*Brook P+ Volunteer*

**Ms Andrea Duncan**

*Department of Health*

**Dr Dawn Wilkinson**

*Chair, BASHH Adolescent Special Interest Group*

**Dr Karen Rogstad**

*Chair, BASHH Advisory Board and Working Group*

**0900–1000**

**ViiV Healthcare Satellite Symposium**

**HIV Treatment So Far So Good ... Can We Do Better?**

**Chair:** Dr Mark Nelson

*Chelsea and Westminster Hospital, London*

**Dr Laura Waters**

*Mortimer Market Centre, London*

**Dr Nicola Mackie**

*St Mary's Hospital, London*

## SATELLITE SYMPOSIA SEMINARS AND WORKSHOPS

### THURSDAY 3 APRIL 2014

*All satellite symposia will be held in Hall 1A, Upper Level  
Locations of workshops and evening seminars are listed below adjacent to the respective events*

1355–1455

**Cepheid Lunchtime Workshop** Room 4B, Upper Level

**Best practice in the management of STIs**

**Chair:** Dr Sharon Hillier

*University of Pittsburgh, USA*

**It's in the SAC!**

Dr Dave Persing

*Cepheid*

**Using the GeneXpert system to improve clinical outcomes in men with NGU**

Dr Paddy Horner

*Bristol Sexual Health Clinic*

**Diagnosis of TV in the GUM clinic: use of *T. vaginalis* TMA**

Dr John White

*Guy's & St Thomas' NHS Foundation Trust, London*

**Debate: *Trichomonas vaginalis*: The hidden epidemic**

Dr Paddy Horner

*Bristol Sexual Health Clinic*

Dr Alan McOwan

*Chelsea and Westminster Hospital, London*

Dr Dave Persing

*Cepheid*

Dr John White

*Guy's & St Thomas' NHS Foundation Trust, London*

1355–1455

**Janssen Lunchtime Workshop** Room 4A, Upper Level

**Maximising the engagement of every patient: the key to improved outcomes in HIV?**

**A case study based, interactive workshop**

**Chair:** Dr Andrew de Burgh-Thomas

*Gloucester Royal Hospital*

Professor Fiona Mulcahy

*St James's Hospital, Dublin, Ireland*

Mr Shaun Watson

*HIV Community Westminster, London*

Ms Silvia Petretti

*Positively UK*





## SATELLITE SYMPOSIA SEMINARS AND WORKSHOPS

**FRIDAY 4 APRIL 2014**

*All satellite symposia will be held in Hall 1A, Upper Level  
Locations of workshops and evening seminars are listed below adjacent to the respective events*

**0900–1000**

**Bristol-Myers Squibb Pharmaceuticals Satellite Symposium**

**Treating today for tomorrow: What you need to know about managing HIV co-morbidities**

**Chair:** Dr Ashish Sukthankar

*Manchester Royal Infirmary*

**Dr Paddy Mallon**

*Mater Misericordiae University Hospital, Dublin, Ireland*

**Dr Marta Boffito**

*Chelsea and Westminster Hospital, London*

**1325–1425**

**Gilead Sciences Lunchtime Workshop Room 4A, Upper Level**

**Positive conversations**

**Chair:** Dr Alan Winston

*Imperial College Healthcare NHS Trust, London*

**Mr Allan Anderson**

*Positively UK*

**Ms Michelle Croston**

*North Manchester General Hospital*

**Ms Maureen Ndawana**

*African Health Policy Network*

**Dr Jenny Petrak**

*Homerton University Hospital, London*

**1325–1425**

**ViiV Healthcare Lunchtime Workshop Room 4B, Upper Level**

**The different faces of people living with HIV**

**Chairs:** Mr Robert Fieldhouse

*Baseline*

**Dr Karen Rogstad**

*Sheffield Teaching Hospitals NHS Foundation Trust*

*Five people living with HIV will be speaking as part of this workshop*

# EXHIBITION FLOOR PLAN AND EXHIBITORS

## Hall 2 Lower Level, Arena and Convention Centre Liverpool



## EXHIBITORS

- |  |  |  |
|--|--|--|
| 1 Birmingham HIV Partnership   | 13 Merz Pharma UK                          | 28 Sahir House   |
| 2 Pregnancy Advisory Services  | 14 National AIDS Trust                     | 29 ViiV Healthcare UK                                      |
| 3 AbbVie Ltd   | 15 Hologic                                 | 30 Mildmay Mission Hospital                                |
| 4 Centre for All Families Positive Health (CAFPH)                                      | 16 Alere                                   | 31 National Institute for Health Research                  |
| 5 SAGE Publications  | 17 National HIV Nurses Association (NHVNA) | 32 Wiley Blackwell   |
| 6 Children's HIV Association (CHIVA)   | 18 Public Health England                   | 33 Janssen Medical   |
| 7 Boehringer Ingelheim   | 19 BBI Healthcare                          | 34 Janssen   |
| 8 Dietitians Working in HIV / AIDS (DHIVA) / Rehabilitation in HIV Association (RHIVA) | 20 Atlas                                   | 35 Bristol-Myers Squibb Pharmaceuticals                    |
| 9 BD Diagnostic Systems  | 21 Terrence Higgins Trust                  | 36 Halve-It  |
| 10 HIV iBase / UK Community Advisory Board (UK-CAB)                                    | 22 6PM Plc                                 | 37 Bristol-Myers Squibb Partnering for Cure                |
| 11 Cepheid   | 23 Blithe Computer Systems                 | 38 African Health Policy Network (AHPN) / The Sophia Forum |
| 12 HIV Pharmacy Association (HIVPA)  | 24 MSD Ltd                                 | 39 Positively UK   |
|  | 25 Takeda                                  | 40 Gilead Sciences   |
|  | 26 Saving Lives                            | 41 Gilead Sciences HCV                                     |
|  | 27 AxSys Technologies                      | 42 Baseline  |


# CONFERENCE INFORMATION

## Arena and Convention Centre Liverpool


Kings Dock · Liverpool Waterfront · Liverpool · Merseyside L3 4FP

Telephone: +44 (0)151 475 8888 · Email: [info@accliverpool.com](mailto:info@accliverpool.com) · Web: [www.accliverpool.com](http://www.accliverpool.com)

### Registration

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence. A delegate pack will be provided as part of your registration. Delegate packs have been sponsored by **Sage Publications**. 

### Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas. The delegate lanyards have been sponsored by **Gilead Sciences**. 

### Accompanying persons *Pre-booked and paid only*

Accompanying persons' fees include attendance at the Welcome Reception Civic Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

### BHIVA / BASHH Lunchtime workshops

Places are limited and will be restricted (80 delegates per workshop and 40 persons per skills workshop). One workshop each day will be held in the main lecture theatre (Hall 1A) and places will not be restricted to attend this session. In this way, it is anticipated that each delegate will be able to attend a minimum of one lunchtime workshop, each day, at conference, if they so wish. Places at each workshop will be available onsite, on a first-come, first-served basis, at the door of the lunchtime workshop. Doors will open 15 minutes prior to the start of each workshop. Each workshop will begin promptly and lunch packs will be provided for delegates attending these sessions, where indicated. Those delegates attending the Lunchtime workshop, held in the lecture theatre will need to collect their lunch in the exhibition hall following the conclusion of the workshop, during the second hour of the lunch period.

### BHIVA / BASHH Workshops supported by travel bursary grants

Sessions supported by means of an educational grant kindly donated by BHIVA / BASHH sponsors are administered by BHIVA / BASHH. All correspondence and liaison with the speakers invited to participate in these sessions has been conducted by BHIVA / BASHH and the speakers are under no obligation to the sponsoring company. Donated bursaries will go towards supporting the honorarium, travel and accommodation of invited conference speakers. The slots are entirely educational in content and form part of the BHIVA / BASHH plenary programme, and thus qualify for CPD accreditation.

### BHIVA / BASHH New Consultants Forum

The BHIVA / BASHH New Consultants Forum will bring together new UK consultants (first 5 years of substantive consultant post, to include those in early locum post and/or those within 6 months of CCT) to discuss topics of mutual interest, to raise issues of concern and to provide feedback on these matters to the BHIVA / BASHH Executive Committee. The Forum will run from 1330–1600 on Tuesday 1 April 2014. Those delegates attending sessions can register for a dinner to be held in the evening following the BHIVA / BASHH Welcome Reception. Sessions comprise four forums, each devoted to a specific theme or topic. Places are limited and in principle have been made available on a first-come, first-served basis.

### Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 87191. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

## CONFERENCE INFORMATION

---

### Social events

There are three social events: a Welcome Reception (Tuesday) to be held at the Arena and Convention Centre Liverpool, a Civic Reception (Wednesday) to be held at Matou Restaurant and a Gala Dinner (Thursday) to be held at St George's Hall. You will require a ticket to gain entry to the Gala Dinner. Please refer to page 30 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

### Poster presentations

All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. There will be three poster sessions, held each day at lunchtime, Wednesday to Friday. All poster presenters should be available by their poster for the final 30 minutes of the Wednesday and Thursday lunchtime sessions for potential discussion with delegates and poster judges. The poster judges will review the posters and subsequently select 15 posters to be highly commended, from which six will be presented as part of the Oral Research Poster Presentations session at 1200–1230 on Friday 4 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1700 on Thursday 3 April to see whether they have been selected. The BHIVA Ian Williams / BASHH Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 4 April at 1430–1445.

### Oral research presentations

Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers' Preview Room located in Hall 3 Foyer in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers' Preview Room to review their slides prior to presentation. The BHIVA Margaret Johnson / BASHH Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 4 April at 1430–1445.

### Accommodation

Please note that the registration fee does not include accommodation. If you have not already arranged accommodation you can do so by referring to the conference website for further details. It is very important to book accommodation early as rates will increase significantly nearer the time of conference, especially as the conference dates immediately precede the Grand National on the Saturday.

### WiFi and internet café

Free WiFi access will be available at the conference centre in Hall 2 (exhibition hall).

### Cloakroom

A manned cloakroom is available onsite on the ground level at the Arena and Convention Centre Liverpool. Items can be deposited each day at £1 per item. All belongings are left at the owner's risk. The British HIV Association and the British Association for Sexual Health and HIV do not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom area.

### Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

### Filming and photography

Please note that all sessions held in the lecture theatre (Hall 1A) will be filmed and uploaded to the BHIVA / BASHH websites following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published either in BHIVA or BASHH publications or on the BHIVA and BASHH websites.

# SCHOLARSHIPS AND AWARDS

## The BHIVA Margaret Johnson / BASHH Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA / BASHH-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

## The BHIVA Ian Williams / BASHH Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA / BASHH-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

## The BHIVA / BASHH Best Abstract Presentation from an Undergraduate

The prize will be awarded for the best oral or poster research presentation during the conference presented by an undergraduate student. All oral and poster research presentations will be judged by a BHIVA / BASHH-appointed research judging panel. The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

## The BHIVA / BASHH Maggie Godley Memorial Prize

This prize will be awarded for the best oral or poster research presentation during the conference presented by a doctor of consultant status (at the time of submission of their abstract on 17 January 2014) who works in a district general non-teaching hospital, in the UK. All oral and poster research presentations will be judged by a BHIVA / BASHH-appointed judging panel. The prize will be presented at the Prizes and Awards Ceremony on Friday 4 April.

## The BHIVA / BASHH Best SpR Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA / BASHH Lunchtime Clinico-Pathological SpR Case Presentations Session and the Pregnancy, Breastfeeding and HIV Case Presentations Session. The prizes will be presented at the Prizes and Awards Ceremony on Friday 4 April.

## Commended Oral Presentations

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA / BASHH-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 4 April.

## Commended Poster Presentations

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA / BASHH-appointed poster research judging panel. The prizes will be awarded at the end of Thursday 3 April. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 4 April.

## Mediscript Awards in collaboration with BHIVA / BASHH

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Friday 4 April.

## BHIVA / BASHH Science Scholarships

Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees, a contribution towards travel expenses and accommodation costs are paid by BHIVA / BASHH to successful candidates.

## BHIVA Community Registrations and Scholarships

Community Scholarships have been awarded to 10 UK-based community registrants to assist them to attend the conference. For those applicants selected, all registration fees and a contribution towards expenses and accommodation costs are paid by BHIVA / BASHH. In addition, BHIVA / BASHH has supported free registration for over 40 community representatives to attend the conference.

## BHIVA Registration Scholarships

Registration Scholarships have been awarded to up to 10 delegates who are either healthcare professionals who are retired, not working, or employed in a part-time or equivalent capacity, or who are students involved in full-time undergraduate or postgraduate work. The scholarship covers the conference registration fee.

## BHIVA / BASHH Registration Support for Educational, Community and Affiliated Organisations

BHIVA / BASHH has provided reduced-cost registration places to over 20 delegates from educational, community and affiliated organisations in order to assist them with exhibiting at the conference.



## SOCIAL EVENTS

### Welcome Reception

#### Arena and Convention Centre Liverpool

Tuesday 1 April 2014: 1930–2030

**A**CC Liverpool is a uniquely flexible venue, the only directly interconnected arena and convention centre in Europe. ACC Liverpool opened its doors for the first time as the city celebrated European Capital of Culture. Since this time a string of accolades have followed, including CONFEX's coveted 'Best UK Venue' for two consecutive years, 'Best Corporate Social Responsibility Initiative' and 'Most Effective Team' at the Exhibition News awards. The venue has hosted international events ranging from the MTV Europe Music Awards and the British Council of Shopping Centres' annual conference to the BBC Sports Personality of the Year.

The Welcome Reception will begin with some short speeches in the lecture theatre (Hall 1A) followed by an opportunity for delegates to network in the exhibition area whilst enjoying a drink and some light refreshments.



#### Programme of events

1930–1945 Speeches  
1945–2030 Drinks and canapés  
2030 Close

### Civic Reception

*Ticket required*

#### Matou Restaurant

Wednesday 2 April 2014: 1915–2030

**M**atou is a modern pan Asian restaurant, cocktail bar and lounge. It is located in a privileged position overlooking the vibrant dock waterfront area of Liverpool, and one of the city's renowned land marks, the Pier Head. Matou provides a unique experience in dining merging dishes from the Far East including Malaysia, Thailand, Singapore, Japan, China.

We are honoured that the Lord Mayor of the City of Liverpool, Councillor Gary Miller, has kindly agreed to speak as part of our Civic Reception at this prestigious venue. The event will begin with a drinks and canapé reception.



#### Programme of events

1915–1945 Drinks and canapés  
1945–2000 Speeches  
2000–2030 Drinks and canapés  
2030 Close

*Entertainment will include a string quartet*

### Gala Dinner

*Ticket required*

**Dress code:** Gentlemen are requested to wear jacket and tie

#### St George's Hall

Thursday 3 April 2014: 2000–0030

**S**t George's Hall is one of the best examples of neo-classical buildings in the world. The impressive Great Hall with its chandeliers, stained glass windows, barrel vaulted ceiling and world-famous Willis Organ make this venue the perfect city centre location for our Gala Dinner.

The Gala Dinner will commence with a drinks reception followed by dinner at St George's Hall. After some short speeches, entertainment will include music by The Toni James Band. The band is an eight-piece ensemble that pride themselves on delivering an energetic and super slick performance that will have everybody up dancing.



#### Programme of events

- Drinks Reception
- Gala Dinner
- Speeches
- Music and dancing

*Please Note: Coaches will not be provided to or from the Gala Dinner*



**Detect it** in here.  
**Stop it** out there.

**Xpert® CT/NG & Xpert® CT:**  
*Three targets, 90 minutes.*  
*End confirmatory testing.*

Achieve same-day detection and containment with Xpert CT/NG. In addition to single-test confidence for CT/NG, our full menu of fast, accurate and easy-to-use molecular tests helps you strengthen antibiotic stewardship, shrink patient stays, advance care, and reduce costs. Welcome to immediate informed decisions.

Cepheid powers same-day results in more than 5,000 locations worldwide.  
**Learn more at [cepheidinternational.com](http://cepheidinternational.com).**

 **Cepheid®**  
A better way.

## BIOGRAPHIES

**Jane Anderson** (Homerton University Hospital NHS Foundation Trust and Public Health England) has been involved in the care of people with HIV since the beginning of the epidemic. Her clinical practice and research focus on the prevention, treatment and care of HIV amongst migrant and ethnic minority populations in the UK. She holds honorary professorial appointments at Queen Mary, University of London and University College London. She is immediate past Chair of the British HIV Association and is an adviser to Public Health England on HIV, sexual and reproductive health matters.

**Vanessa Apea** is a Consultant in GU/HIV Medicine at Barts Health NHS Trust. Her clinical and research interests are in the provision of sexual health and HIV care for marginalised groups, community outreach and global health service delivery. She is the lead for the management of those hard to engage in care at the Grahame Hayton Unit. She is also the BASHH North Thames Audit Chair.

**David Asboe** is a Consultant in HIV Medicine and Sexual Health at Chelsea and Westminster Hospital. He studied medicine at Otago University Medical School, New Zealand and completed specialist training at St Thomas' Hospital London. He is Divisional Research Lead and his research interests are antiretroviral resistance and the sexual health of people living with HIV. He is the Convenor of the Diploma in HIV Medicine, and is a Trustee on the Executive Committee of the British HIV Association. He was elected as BHIVA Chair in 2013.

**Dola Awoyemi** is an HIV/GUM specialist pharmacist at Kingston Hospital NHS Foundation Trust. She has an interest in public health programmes in developing countries and is currently completing a Masters in Public Health, health service management stream at the London School of Hygiene and Tropical Medicine.

**Abdel Babiker** is a Scientific Programme Leader at the MRC Clinical Trials Unit and a Professor of Epidemiology and Medical Statistics at UCL. He has worked for many years on the development and implementation of clinical trials in HIV and other infections including more recently the SPARTAC and NEAT 001 trials. He currently co-chairs the START trial, conducted by the INSIGHT network, and sits on the WHO/TDR Advisory Committee on Research in Integrated Community Case Management of Childhood Illness.

**David Back** is a Professor of Pharmacology at the University of Liverpool and has worked in the area of Pharmacokinetics and drug-drug interactions for more than 35 years. He established the Liverpool HIV Pharmacology Group (LHPG) in 1987 and subsequently the Liverpool group has been at the forefront of pharmacological research of anti-infective drugs. Currently there are numerous ongoing pharmacokinetic, pharmacogenetic and molecular- based studies involving local, national and international collaborations. David has authored ~400 publications. He is a former Editor of the British Journal of Clinical Pharmacology and is on the Editorial Board of numerous journals. He has established several key resources for health care professionals including [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org) and [www.hep-druginteractions.org](http://www.hep-druginteractions.org). In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for Outstanding Contribution to Clinical Pharmacology.

**Ravneet Batra** is a Consultant Liaison Psychiatrist with special interest in blood-borne viruses and is based full time at the Regional Infectious Diseases Unit in Edinburgh. Ravneet is involved in the policy guidelines and all aspects of delivery of care for mental health problems associated with bloodborne viruses and its treatments.

**Mas Chaponda** is a Consultant Physician in HIV Medicine within the subdirectorates of Infectious Diseases and Clinical Pharmacology, Royal Liverpool University Hospitals NHS Trust. The position combines the expertise of the Tropical Infectious Diseases Unit, HIV Pharmacology and the Liverpool Centre for Sexual Health. In addition, Dr Chaponda is a key figure in the Cheshire, Mersey and North Wales HIV clinical network. Dr Chaponda is a BHIVA Executive Committee member as well as a Clinical Representative on the National HIV Clinical Reference Group (CRG). His interests include HIV drug interactions, TB and clinical trials.

**Jan Clarke** is a Consultant in Genitourinary Medicine at the Leeds Teaching Hospitals Trust. A former Treasurer and General Secretary of BASHH, she has chaired the Public and Patient Engagement group for the past 2 years. Her professional interests include adolescent and paediatric aspects of GU medicine, mentoring for clinicians, and partner notification for STIs.



## BIOGRAPHIES

**James Coutts** trained at Oxford University Medical School, with medical qualification in 1989. He became a member of the Royal College of Physicians by examination in 1992, and subsequently a fellow in 2006. After training in general medicine he undertook three years' training in Intensive care, before specialising in cardiology. He was appointed consultant cardiologist at Guy's and St Thomas' Hospitals in 2002. He has a specialist interest in coronary intervention (angiography and angioplasty for ischaemic heart disease), in addition to working in general cardiology and general medicine.

**Subathira Dakshina** is a Specialist Registrar (ST4) in HIV and Sexual Health at Royal London Hospital, Barts Health NHS Trust.

**Annemiek de Ruiter** is a Consultant Physician in HIV/GUM at St Thomas' Hospital, London and has managed HIV-positive patients for over 20 years, specialising in the management of pregnant women with HIV. She has published extensively, formed local and national networks, collaborated widely, advised at a national level, lectured nationally and internationally, and led the development of the BHIVA 2012 and 2014 Pregnancy guidelines. She is the BHIVA Honorary Secretary and sits on the BHIVA Conferences and Guidelines subcommittees.

**Carol Emerson** is a Consultant in HIV/GUM in Belfast. She is currently the Co-chair of the BASHH & BHIVA Mentoring Group and sits on the BHIVA Conferences Subcommittee. As the past new consultant BHIVA representative she worked hard on the BHIVA Executive Committee for recently appointed consultants and set up the new consultant forum.

**Dr Claudia Estcourt** is Reader in Sexual Health and HIV at Barts and The London School of Medicine and Dentistry, and Consultant at Barts Health NHS Trust. Her major research interests focus on public health and health service interventions to control STIs, latterly focusing on methods of improving partner notification, and near-patient STI diagnostics and remote web-based STI management. Other strands of work include web-based safer sex interventions, and development of new tests for whole genome sequencing of STI pathogens. She is enthusiastic about multidisciplinary clinical skills learning & teaching both in the UK and in developing countries, whilst clinically, she focuses on complex female sexual health and outpatient HIV medicine in East London.

**Christopher Fairley** is Director of Melbourne Sexual Health Centre and Professor of Public Health at Monash University. His main research interests are the clinical and public health aspects of the control of sexually transmitted infections.

**Kate Folkard** is National Chlamydia Screening Programme Manager at Public Health England. She is also managing work that PHE is leading on the development of a framework for whole system approach to commissioning of HIV, sexual and reproductive health services. Kate was previously a sexual health commissioner in a PCT and has extensive experience across local and national government, health and third sector.

**Emma Fox** is a Consultant in Genitourinary/HIV Medicine in Kent Community Health Trust, having previously held consultant posts at St George's Hospital and Guy's and St Thomas' Hospitals. She was a founding member of the BASHH Mentoring Group and is currently Co-chair of the BASHH/BHIVA Mentoring Group.

**Linda Furness** is a Senior Sexual Health Adviser at Cardiff Royal Infirmary Department of GUM and the SSHA NPC Welsh representative.

**Brian Gazzard** started the HIV unit at the Chelsea and Westminster Hospital and is now its Clinical Research Director. This is one of the largest clinical units in Europe, concentrating its research mainly on new algorithms of care, immunological and oncological manifestations of HIV disease and antiretroviral therapy. Brian Gazzard qualified at Cambridge and received his MD from that institution in 1983. He was awarded the Department of Health prize for distinguished achievement in 2002 and is the Chairman of the Expert Group Advising Chief Medical Officer of Health on matters relating to HIV disease.

**Anna Maria Geretti** is Professor of Virology & Infectious Diseases at the Institute of Infection & Global Health, University of Liverpool. Anna Maria's clinical and research activities focus on HIV and viral hepatitis, with a specific interest in antiviral therapy, virus genetic diversity, and diagnostics, and she has over 100 publications. She contributes to national and international management guidelines, is Secretary of EACS, and founding member of the British Society for NanoMedicine. Anna Maria runs programmes in resource-limited settings and enthusiastically shares her expertise to train doctors and scientists.

## BIOGRAPHIES

**Dame Anne Johnson** is Professor of Infectious Disease Epidemiology at University College London and Honorary Public Health Consultant at Central and North West London NHS Foundation Trust. She has been Principal Investigator on the National Survey for Sexual Attitudes and Lifestyles 1990, 2000 and 2010, and is a Governor of the Wellcome Trust.

**Saye Khoo** is an Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the School of Biomedical Sciences at the University of Liverpool. His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved by individualised care through understanding why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics and drug interactions), and identifying vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modelling approaches.

**Mark Lawton** is a Consultant in Sexual Health & HIV in Liverpool. His interests include HPV and the sexual health needs of MSM. He is delighted to be co-facilitating the workshop on 'legal responses to HIV & other STIs' with Professor Weait – a complex but important topic.

**Sebastian Lucas** has worked on the pathology of HIV/AIDS since 1982, and continues in part-retirement (but still based at St Thomas' Hospital). His interests are the clinico-pathological correlation of HIV disease, diagnostics of opportunistic diseases, the direct pathology induced by HIV, and the complications of cART and of increasing age in HIV-infected persons.

**Fiona Lyons** is a Consultant in GU/HIV Medicine at the GUIDE clinic, St James's Hospital, Dublin, Ireland, where she is Joint Clinical Lead for HIV in Pregnancy. Her special interests include HIV infection in women and in pregnancy. She is joint author of the Irish Guidelines for the Management of HIV in Pregnancy and has acted as an external assessor for the BHIVA HIV in Pregnancy guidelines.

**Alan McOwan** has a particular interest in early diagnosis and reduction of undiagnosed HIV in MSM. He introduced the UK's first NHS HIV point-of-care testing services in 2002. The testing projects he has developed now diagnose 1 in 6 of the UK's new HIV in MSM. Alan has pioneered the use of social media to offer home HIV sampling to high -risk MSM. This innovative model of care won the 2013 BMJ Award for 'Transforming Healthcare Using Technology'.

**Christina Marra** completed residency training in Neurology and fellowship training in Infectious Diseases. She is Professor of Neurology with an adjunct appointment in Medicine (Infectious Diseases) at the University of Washington in Seattle, Washington, USA. She directs a research program on neurosyphilis, participates in multi-centre clinical research on the neurological consequences of HIV and provides neurological care in a multispecialty HIV clinic.

**Anatole Menon-Johansson** is the Clinical Lead for Sexual Health at Guy's & St Thomas' NHS Foundation Trust that includes the seven-day-a-week Burrell Street Sexual Health Clinic ([www.burrellstreet.co.uk](http://www.burrellstreet.co.uk)), the Clinical Director of the charity Brook ([www.brook.org.uk](http://www.brook.org.uk)) and founder of the sexual health information and real time sign posting service SXT ([www.sxt.org.uk](http://www.sxt.org.uk)).

**Alastair Miller** is a Consultant Physician at the Tropical & Infectious Disease Unit at Royal Liverpool University Hospital and Honorary Fellow at Liverpool School of Tropical Medicine. He manages a large outpatient HIV cohort and numerous complex inpatients and has been involved in HIV care since 1984. He is a Co-investigator on PIVOT trial. He sits on the BHIVA Education and Scientific Subcommittee and is Chair of the BHIVA Conferences Subcommittee.

**Eileen Nixon** has been a Nurse Consultant in HIV since 2004. She has served on the NHVNA Executive Committee and was co-author of the National HIV Nursing Competencies. Eileen has just completed a PhD exploring HIV models of care and she currently represents NHVNA members on the HIV Clinical Reference Group.

**Nick Paton** is an Infectious Diseases Physician and Clinical Researcher. His research interests are in therapeutic clinical trials for HIV and TB, particularly of interventions that are relevant to resource-limited settings. In 2011, he took up a Chair of Infectious Diseases at the National University of Singapore, where he leads a programme of TB translational research and trials. He continues involvement with the MRC Clinical Trials Unit as the Chief Investigator on the PIVOT and EARNEST trials.



## BIOGRAPHIES

**Massimo Puoti** is a Specialist in Infectious Diseases and Gastroenterology with a particular interest in hepatitis and HIV infection. He is the Director of the Infectious Diseases Department in the largest hospital in Milan, the AO Niguarda Ca' Granda.

**Michael Rayment** is currently a Locum Consultant in Sexual Health and HIV Medicine at Homerton University Hospital. His main clinical interest is sexual health and HIV prevention in MSM. Michael's main research interest is the evaluation of HIV testing strategies to reduce undiagnosed and late-diagnosed HIV infection in the UK.

**Andrew Riordan** is a Consultant in Paediatric Infectious Diseases and Immunology at Alder Hey Children's NHS Foundation Trust in Liverpool. He was a Committee member of the Children's HIV Association and was the Lead Clinician for the North West Children's HIV Network 2010–2013.

**Daniel Richardson** is a Consultant Physician in Sexual Health & HIV at Brighton & Sussex University Hospitals NHS Trust, and Honorary Senior Lecturer at Brighton & Sussex Medical School. He trained in GU Medicine at St Mary's in Paddington. He is currently the BASHH Conference Secretary. Daniel's research interests are in the sexual health of men who have sex with men.

**Dana Rosenfeld** is a Senior Lecturer in Sociology, Keele University and medical sociologist and social gerontologist with particular interests in ageing and the life course, HIV and ageing, and the lived experience of chronic illness and disability. She was Lead Investigator on the MRC-funded HIV and Later Life study (2011–2013).

**Jonathan Ross** is Professor of Sexual Health and HIV and has worked as a Consultant Physician in Sexual Health and HIV Medicine in Birmingham since 1997. He is treasurer for the British Association for Sexual Health and HIV, editor of *STD Global Update* and sits on the IUSTI World Executive Committee. He is also an associate editor of the journal *Sexually Transmitted Infections*, a member of the editorial board for European Sexually Transmitted Diseases Guidelines and Chairman of the Neurology Specialty Question Group for the MRCP examination. He is the author of UK and European Guidelines on Pelvic Inflammatory Disease and editor of the UK National Screening and Testing Guidelines for STDs. He is on the Editorial Board of the Cochrane Collaboration Sexually Transmitted Diseases Collaborative Review Group and *International Journal of STD and AIDS* journal. His research interests are pelvic infection, gonorrhoea, Mycoplasma genitalium, HIV and sexual health care service delivery.

**Ann Sullivan** trained in Australia and London, gaining an MD in HIV Immunology. She is now a Consultant at Chelsea and Westminster Hospital. Her specific interests include expanding HIV testing, MSM sexual health and utilising technology to improve patient care and experience. As a member of both BASHH and BHIVA audit groups she led the recent National HIV Partner Notification audit.

**Alexandra Teleka** graduated from the University of Malawi in 2010 with a Bachelor of Medicine and Surgery. She worked at Kamuzu Central Hospital for 2 years and is currently working as District Medical Officer at Blantyre District Health Office.

**Analia Urena** is an Infectious Diseases Specialist and staff member at Helios Salud, which is a private ambulatory care centre for HIV-infected people in Argentina. She is also a medical staff member of the National Programme for the Control of Vaccine-Preventable Diseases of the Ministry of Health in Buenos Aires, Argentina.

**Andrew Ustianowski** is a Consultant Physician in Infectious Diseases & Tropical Medicine, and Clinical Director, at the Monsall Regional Infection Unit, North Manchester General Hospital, which has a cohort of over 2000 HIV-positive patients. He is also chair of the British Viral Hepatitis Group, represents on the Clinical Reference Group for Infectious Diseases, is part of guideline writing committees for BHIVA and other bodies, lectures widely on HIV, hepatitis and related topics, and is involved in several educational steering groups.

**Laura Waters** is a GU/HIV Consultant at the Mortimer Market Centre, London, working in HIV and hepatitis outpatient and HIV in-patient services. She completed specialist training in 2006 then worked in clinical trials at Chelsea & Westminster and Brighton, completing an MD on the simplification and switch of antiretrovirals. She has published and presented widely on topics including drug toxicity and contraception for HIV-positive women. She is chair of the BASHH HIV special interest group and is Vice Chair of the BHIVA Guidelines Subcommittee.

## BIOGRAPHIES

**Matthew Weait** is Professor of Law and Policy and Pro-Vice-Master at Birkbeck, University of London. He was a member of the Technical Advisory Group for the Global Commission on HIV and the Law, and an advisor to the European AIDS Treatment Group. Matthew was the legal and ethics advisor for the PARTNER study, and has published widely on the criminalisation of HIV.

**Jonathan Weber** is the Jefferiss Professor of Communicable Diseases and GU Medicine at Imperial College London. He has researched HIV vaccines since 1990: as PI for the first UK HIV vaccine study in 1991 (Ty.VLP); the MRC/SK-B rgp120 (W61D) programme; the EuroVacc on DNA-NYVAC studies; and currently the Wellcome Trust UK HIV Vaccine Consortium developing DNA-prime, modified poxvirus boost, protein/adjuvant re-boost strategies.

**John White** is an Australian Sexual Health Physician who has been working in the UK since 2004 as a Consultant Physician in the Department of Genitourinary Medicine at Guy's and St Thomas' Hospitals in London. His professional interests include bacterial STIs, sexual health of men who have sex with men (MSM) and diagnostic tests for HIV/STIs. He has a keen interest in lymphogranuloma venereum infection in MSM and is involved in several research studies involving the assessment of diagnostic tests for bacterial STIs and HIV. He is Chair of the British Association of Sexual Health & HIV Education Committee and also sits on the Core Group of the European Collaborative Clinical Group of the International Union against Sexually Transmitted Infections (IUSTI). Since 2009 he has been Editor-in-Chief of the *International Journal of STD & AIDS*.

**Janet Wilson** is a Consultant in Sexual Health and HIV in Leeds and is the Past-President of BASHH. As President she wrote to all Local Authority CEOs about the potential problems associated with tendering of sexual health services. She was a member of the group producing the BASHH National Standards for the Management of STIs 2014. Her main areas of research interest are the application and cost-effectiveness of diagnostic tests; infections in pregnancy (including HIV); and recurrent vaginal infections.

**Adam Winstock** is a Consultant Addiction Psychiatrist at the South London and Maudsley NHS Trust and Senior Lecturer at the Institute of Psychiatry. He has written over 100 papers and book chapters. He is also founder of Global Drug Survey which runs the world's biggest drug survey and developer of the online and smartphone apps the drugsmeter ([www.drugsmeter.com](http://www.drugsmeter.com)) and drinksmeter ([www.drinksmeter.com](http://www.drinksmeter.com)).



## NOTES

[illegible]

## SPONSORS AND EXHIBITORS

### CONFERENCE SPONSORS

#### AbbVie Ltd

Abbott House  
Vanwall Business Park  
Maidenhead  
Berkshire SL6 4XE



#### BD Diagnostics

The Danby Building  
Edmund Halley Road  
Oxford Science Park  
Oxford OX4 4DQ



#### Boehringer Ingelheim Ltd

Ellesfield Avenue  
Bracknell  
Berkshire RG12 8YS



#### Bristol-Myers Squibb Pharmaceuticals Ltd

Uxbridge Business Park  
Sanderson Road  
Middlesex UB8 1DH



#### Cepheid UK Limited

Jupiter House  
Mercury Park  
Wooburn Green  
Buckinghamshire HP10 0HH



#### Gilead Sciences Ltd

Granta Park  
Great Abington  
Cambridgeshire CB21 6GT



#### MSD Ltd

Hertford Road  
Hoddesdon  
Hertfordshire EN11 9BU



#### Janssen

50-100 Holmers Farm Way  
High Wycombe  
Buckinghamshire HP12 4DP



#### ViiV Healthcare UK Ltd

Stockley Park West  
Uxbridge  
Middlesex UB11 1BT



### CONFERENCE EXHIBITORS

#### Pharmaceutical and Commercial

6PM Plc

Alere

Atlas

AxSys Technologies

BBI Healthcare

Blithe Computer Systems

Hologic

Merz Pharma UK

Pregnancy Advisory Services

Takeda

#### Affiliated, Educational and Charitable

Birmingham HIV Partnership

Children's HIV Association (CHIVA)

Dietitians Working in HIV/AIDS (DHIVA)

Halve It

HIV Pharmacy Association (HIVPA)

Mildmay Mission Hospital

National HIV Nurses Association (NHIVNA)

National Institute of Health Research (NIHR)

Public Health England

Rehabilitation in HIV Association (RHIVA)

SAGE Publications

Saving Lives

Wiley Blackwell

#### Community

African Health Policy Network (AHPN)

Baseline

Centre for All Families Positive Health (CAFPH)

HIV i-Base

UK Community Advisory Board (UK-CAB)

National AIDS Trust (NAT)

Positively UK

Terence Higgins Trust

The Sophia Forum

Sahir House

# HIV Select

a comprehensive HIV services toolkit developed by Janssen, for now and for the future.

HIV Select was developed following research into the unmet needs of health care professionals and patients, with input from a steering group of HIV specialists. The toolkit provides information on Janssen products, tools for patient care and case management, and resources to support healthcare providers throughout their patient's journey. Janssen is dedicated to providing new services to HCPs and Patients. We hope that you find this toolkit useful.

## Efficiency Tools

- Case Management
- Integrated Care Pathway
- HIV Database and HARS Collection Tool
- Service Redesign Model

## Patient Tools

- Adherence Kit

## Health Care Professional tools

- Medical Scholarships
- Medical Education
- Patient Portraits, case study based meetings developed by clinicians for clinicians
- T3 - Think, Talk, Test an anti-stigma campaign

**For more information please contact  
your local Janssen Account Manager.**



Visit the  
Viiv Healthcare  
stand today to learn  
more about Tivica<sup>®</sup>

# defy

CONVENTION

Introducing a reason to rethink  
first-line treatment in HIV.

- Rapid and sustained efficacy through to 96 weeks<sup>1-5</sup>
- High barrier to resistance<sup>1-5</sup>
- Generally well tolerated with few discontinuations<sup>1-5</sup>
- Once daily with few DDIs or dosing restrictions<sup>6\*</sup>

\*TIVICAY is dosed 50 mg once daily for patients without documented or clinically suspected resistance to the integrase class. TIVICAY should be dosed 50 mg twice daily in patients with resistance to the integrase class (documented or clinically suspected) or in patients taking certain concomitant medicines (e.g. efavirenz, nevirapine, tipranavir/r, or rifampicin).<sup>6</sup>

## Tivica<sup>®</sup> ▼ (dolutegravir) Prescribing Information (Refer to SPC before prescribing)

**Presentation:** 50mg film-coated tablets of dolutegravir. **Indications:** Treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age, in combination with other anti-retroviral medicinal products. **Dosage and administration:** For use by physicians experienced in management of HIV infection. *Adults infected with HIV-1 without documented or clinically suspected resistance to the integrase class:* 50mg once daily with or without food. *Adults with resistance to the integrase class (documented or clinically suspected):* 50mg twice daily, preferably with food to enhance exposure (particularly in patients with Q148 mutations). Dolutegravir use should be informed by integrase resistance pattern. The recommended dose of Tivica is 50mg twice daily when co-administered with efavirenz, nevirapine, tipranavir/ritonavir or rifampicin. *Adolescents aged 12 years and above (weighing at least 40kg) without integrase resistance:* 50mg once daily with or without food. *Children less than 12 years or weighing <40kg:* insufficient data to recommend a dose. *Elderly:* Limited data in patients over 65 years of age. *Renal impairment:* No dosage adjustment required in mild, moderate or severe (CrCl<30ml/min, not on dialysis) renal impairment. *Hepatic impairment:* No dosage adjustment required in mild or moderate hepatic impairment. No data in severe hepatic impairment. **Contraindications:** Hypersensitivity to dolutegravir or to any of the excipients. Co-administration with dofetilide. **Warnings and precautions:** Hypersensitivity reactions have been reported characterised by rash, constitutional findings, and organ dysfunction, including severe liver reactions. Discontinue dolutegravir and other suspect agents immediately if signs or symptoms of hypersensitivity reactions develop. Delay in stopping treatment may result in a life-threatening reaction. Monitor clinical status including liver aminotransferases and bilirubin. Institution of combination antiretroviral therapy may result in an inflammatory reaction to asymptomatic or residual opportunistic pathogens and cause serious clinical conditions, or aggravation of symptoms. Liver biochemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis B and/or C co-infected patients at the start of dolutegravir therapy. Monitoring of liver biochemistries in hepatitis B and/or C co-infection is recommended. Initiate or maintain effective hepatitis B therapy when starting dolutegravir in hepatitis B co-infection. Osteonecrosis has been reported, particularly with acknowledged risk factors, advanced HIV disease or long-term combined antiretroviral exposure. Avoid factors that decrease dolutegravir exposure in the presence of integrase class resistance, including co-administration with medicinal products that reduce dolutegravir exposure (e.g. magnesium/aluminium-containing antacids, iron and calcium supplements, multivitamins and inducing agents, tipranavir/ritonavir, rifampicin and certain antiepileptic drugs). Careful monitoring required with concomitant metformin. **Interactions:** Dolutegravir is metabolised mainly by UGT1A1. Co-administration with medicinal products inhibiting UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or Pgp may increase plasma concentration. Dolutegravir is a substrate for UGT1A3, UGT1A9, CYP3A4, Pgp, and BCRP; medicinal

products inducing those enzymes may decrease dolutegravir plasma concentration and reduce its therapeutic effect. Dolutegravir may increase plasma concentrations of OCT2 dependent drugs (e.g. dofetilide, metformin). Avoid co-administration with enzyme inducers including anticonvulsants and St John's Wort. Administer dolutegravir 2 hours before or 6 hours after magnesium/aluminium-containing antacids, calcium, iron or multivitamin supplements. Dose with 50mg twice daily when co-administered with efavirenz, nevirapine, tipranavir/ritonavir or rifampicin. Consider alternative agents to these and fosamprenavir/ritonavir where possible in integrase resistant patients. Co-administration with etravirine is not recommended unless concomitant atazanavir + ritonavir, lopinavir + ritonavir or darunavir+ritonavir are given. **Pregnancy and lactation:** Not recommended in pregnant women. Avoid breast-feeding. **Side effects:** See SPC for full details. Very common (>1/10): headache, diarrhoea, nausea. Common (>1/100 to <1/10): insomnia, abnormal dreams, dizziness, vomiting, flatulence, abdominal pain or discomfort, rash, pruritus, fatigue, elevations of ALT, AST and CPK. Uncommon (>1/1,000 to <1/100): hypersensitivity, Immune Reconstitution Syndrome, hepatitis. Serum creatinine increases within the first week of treatment and remains stable through 48 weeks (mean change from baseline 9.96 µmol/L). Creatinine increases were comparable by background regimen. These changes do not reflect alteration in glomerular filtration rate. **Basic NHS costs:** £498.75 for 30 tablets (Licence number: EU/1/13/892/001). **Marketing authorisation holder:** Viiv Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

POM

Tivica is a registered trade mark of the Viiv Healthcare Group of Companies  
Date of approval: January 2014 Zinc code: UK/DLG/0055/13(2)

Adverse events should be reported. For the UK, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). For Ireland, adverse events should be reported directly to the IMB, Pharmacovigilance Section, Irish Medicines Board, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Tel: +353 1 6764971. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 in the UK or 1800 244 255 in Ireland.

**References:** 1. Walmsley SL et al. *N Engl J Med*. 2013;369:1807-1818. 2. Raffi F et al. *Lancet*. 2013;381(9868):735-743. 3. Raffi F et al. *Lancet Infect Dis*. 2013;13:927-935. 4. Feinberg J et al. ICAAC. September 10-13, 2013. Denver, Colorado. 5. Cahn P et al. (published online July 3, 2013). *Lancet*. 2013;382(9893):700-708. 6. TIVICAY (dolutegravir) Summary of Product Characteristics, 01/2014.

UK/DLG/0068/13(1)a  
Date of preparation: February 2014

**Viiv Healthcare** TIVICAY is a trademark of the Viiv Healthcare group of companies.  
©Viiv Healthcare group of companies 2014. All rights reserved.

**Tivica<sup>®</sup> ▼**  
dolutegravir